<input id="60gc0"><u id="60gc0"></u></input>
<input id="60gc0"><u id="60gc0"></u></input>
  • <input id="60gc0"><acronym id="60gc0"></acronym></input><menu id="60gc0"></menu>
  • <object id="60gc0"><u id="60gc0"></u></object>
  • <input id="60gc0"><u id="60gc0"></u></input>
    <input id="60gc0"></input>
  • CFDA Granted Approval of Phase I-III Clinical Trials for Sirotinib (XZP - 5491)

    Clinical Trials of Sirotinib (XZP - 5491) by CFDA with the Approval Numbers of 2016L06493 and 2016L06497. ...

    Detail >
    2016-08-04 15:252013-12-24 9:50
    Phase II/ III Clinical Trials of Imigliptin Hydrochloride (KBP-3853) have been approved by CFDA; the Clinic...
    2015-08-26 08:202013-12-24 9:50
    Dr. Frank Wu (CEO, Shandong Xuanzhu Pharma Co., Ltd. and specially appointed National Thousand Talents Program...
    2015-08-07 16:412013-12-24 9:50
    CFDA approved our IND application of Pirotinib Hydrochloride (KBP-5209) today and more importantly granted us a...
    2015-07-17 14:362013-12-24 9:50
    IND filing of Sirotinib (XZP-5491), submitted at the end of June 2015, has been approved by CFDA (The filing numbers are CXHL1501499 and CXHL1501499).
    2015-07-17 14:322013-12-24 9:50
    On May 30th, the 2nd basketball tournament was held at XuanZhu. Seven teams from different divisions fough...
    2015-06-16 08:172013-12-24 9:50
    Pirotinib, a proprietary oncology drug developed by XuanZhu Pharma, has achieved a significant milestone - The fir...

    Email | Terms of Use | Contact us

    2014版權?軒竹醫藥科技有限公司保留所有權利 魯ICP備09030169號

    在线aav片线 - 视频 - 在线观看 - 影视资讯 - 品善网